Tarsus Pharmaceuticals, Inc. financial data

Symbol
TARS on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
15440 Laguna Canyon Road, Irvine, California
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
Q1 2024 - May 8, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 885 % -47.3%
Debt-to-equity 28.6 % +63.9%
Return On Equity -71.1 % -115%
Return On Assets -55.3 % -96.6%
Operating Margin -821 % -238%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 37.8M shares +41.3%
Common Stock, Shares, Outstanding 37.7M shares +40.9%
Entity Public Float 460M USD +155%
Common Stock, Value, Issued 6K USD +20%
Weighted Average Number of Shares Outstanding, Basic 35.3M shares +32%
Weighted Average Number of Shares Outstanding, Diluted 35.3M shares +32%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 27.6M USD +1005%
Research and Development Expense 50M USD +16.6%
General and Administrative Expense 51.6M USD +242%
Costs and Expenses 65.3M USD +138%
Operating Income (Loss) -156M USD -129%
Nonoperating Income (Expense) 7.69M USD +168%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -136M USD -119%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -148M USD -127%
Earnings Per Share, Basic -4.75 USD/shares -96.3%
Earnings Per Share, Diluted -4.75 USD/shares -96.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 194M USD +194%
Marketable Securities, Current 105M USD -22.5%
Accounts Receivable, after Allowance for Credit Loss, Current 29.9M USD +1095%
Inventory, Net 4.04M USD
Assets, Current 341M USD +63.3%
Property, Plant and Equipment, Net 1.34M USD +12.2%
Operating Lease, Right-of-Use Asset 2.13M USD +295%
Intangible Assets, Net (Excluding Goodwill) 3.77M USD
Other Assets, Noncurrent 1.32M USD +149%
Assets 349M USD +65.4%
Employee-related Liabilities, Current 5.96M USD +41.7%
Contract with Customer, Liability, Current 0 USD -100%
Liabilities, Current 42.5M USD +221%
Operating Lease, Liability, Noncurrent 1.61M USD
Other Liabilities, Noncurrent 1.61M USD +3915%
Liabilities 74.1M USD +95.9%
Accumulated Other Comprehensive Income (Loss), Net of Tax -63K USD +10%
Retained Earnings (Accumulated Deficit) -280M USD -112%
Stockholders' Equity Attributable to Parent 275M USD +58.7%
Liabilities and Equity 349M USD +65.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -37.8M USD -72%
Net Cash Provided by (Used in) Financing Activities 109M USD +2070%
Net Cash Provided by (Used in) Investing Activities -102M USD -1005%
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 37.7M shares +40.9%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -31.2M USD -452%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 194M USD +194%
Interest Paid, Excluding Capitalized Interest, Operating Activities 868K USD +46.4%
Deferred Tax Assets, Valuation Allowance 60.3M USD +139%
Deferred Tax Assets, Gross 61M USD +141%
Operating Lease, Liability 2.19M USD
Depreciation 810K USD +146%
Payments to Acquire Property, Plant, and Equipment 174K USD -48.8%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -148M USD -127%
Lessee, Operating Lease, Liability, to be Paid 2.7M USD
Property, Plant and Equipment, Gross 2.8M USD +51.9%
Operating Lease, Liability, Current 585K USD -16.8%
Lessee, Operating Lease, Liability, to be Paid, Year Two 994K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 961K USD
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure
Deferred Income Tax Expense (Benefit) 0 USD
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 343K USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 83K USD
Deferred Tax Assets, Operating Loss Carryforwards 25.9M USD +287%
Preferred Stock, Shares Issued 0 shares
Deferred Federal Income Tax Expense (Benefit) 0 USD
Current Income Tax Expense (Benefit) 0 USD
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 3.93M USD +15.8%
Lessee, Operating Lease, Liability, to be Paid, Year Four 0 USD
Additional Paid in Capital 556M USD +81.8%
Preferred Stock, Shares Outstanding 0 shares
Current State and Local Tax Expense (Benefit) 0 USD
Current Federal Tax Expense (Benefit) 0 USD
Amortization of Intangible Assets 100K USD
Deferred Tax Assets, Net of Valuation Allowance 733K USD +496%
Share-based Payment Arrangement, Expense 21.4M USD +46%
Deferred State and Local Income Tax Expense (Benefit) 0 USD
Interest Expense 3.65M USD +42%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%